Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Change in Receivables (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Change in Receivables for 8 consecutive years, with $4000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables rose 121.05% to $4000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$184000.0, a 94.43% increase, with the full-year FY2024 number at -$672000.0, down 471.27% from a year prior.
  • Change in Receivables was $4000.0 for Q3 2025 at Precision Biosciences, up from -$4000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $9.3 million in Q1 2021 to a low of -$49.8 million in Q3 2022.
  • A 5-year average of -$4.0 million and a median of -$26000.0 in 2023 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: surged 220.08% in 2021, then crashed 51940.0% in 2023.
  • Precision Biosciences' Change in Receivables stood at -$18.8 million in 2021, then soared by 100.03% to $5000.0 in 2022, then plummeted by 51940.0% to -$2.6 million in 2023, then skyrocketed by 101.58% to $41000.0 in 2024, then plummeted by 90.24% to $4000.0 in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Change in Receivables are $4000.0 (Q3 2025), -$4000.0 (Q2 2025), and -$225000.0 (Q1 2025).